EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis

Zimu Wang, Qiuxia Wu, Yu Yao, Mengshu Cao, Jingjing Ding, Yonglong Xiao, Xinmei Huang, Jing Luo

International Immunopharmacology · 2026-07 · 181 · 116793

DOI: 10.1016/j.intimp.2026.116793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-07. Verfasst von Zimu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanj…. Hauptthemen laut MEDLINE: CCAAT-Enhancer-Binding Protein-beta, Idiopathic Pulmonary Fibrosis, N-Terminal Acetyltransferase E, Integrin alpha Chains. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying novel therapeutic targets is urgent for idiopathic pulmonary fibrosis (IPF), a fatal disease with limited treatment options. N-acetyltransferase 10 (NAT10), the sole enzyme responsible for RNA N4-acetylcytidine (ac4C) modification, is implicated in diverse pathological processes. This study aimed to validate NAT10 as a potential therapeutic target for pulmonary fibrosis by utilizing the established small-molecule inhibitor, Remodelin, to functionally interrogate its role. We observed that NAT10 was significantly upregulated in lung tissues from IPF patients and bleomycin (BLM)-treated mice. Pharmacological blockade of NAT10 activity using Remodelin significantly attenuated lung structural destruction and collagen deposition in vivo. In vitro, inhibiting NAT10 function suppressed fibroblast activation and extracellular matrix production. Mechanistically, rather than directly modifying effector molecules, NAT10 stabilized the mRNA of transcription factor C/EBPβ via ac4C modification. This stabilization led to the transcriptional upregulation of Integrin α11 (ITGA11), thereby promoting fibroblast activation. Rescue experiments confirmed that the pro-fibrotic effects of NAT10 are dependent on this C/EBPβ-ITGA11 axis via its acetyltransferase activity. Collectively, our findings characterize NAT10 as a key pathogenic driver and demonstrate that inhibition of this epigenetic regulator offers a promising therapeutic strategy for ameliorating pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CCAAT-Enhancer-Binding Protein-betaIdiopathic Pulmonary FibrosisN-Terminal Acetyltransferase EIntegrin alpha ChainsAnimalsHumansBleomycinMiceFibroblastsLungMice, Inbred C57BLMaleCytidinePulmonary FibrosisBenzoatesNitrobenzenesPyrazolonesN-Terminal Acetyltransferases

Stichwörter der Autor:innen

C/EBPβFibroblast activationITGA11NAT10Pulmonary fibrosisac4C

Substanzen

CCAAT-Enhancer-Binding Protein-betaBleomycinN-Terminal Acetyltransferase ENAT10 protein, humanIntegrin alpha Chains4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acidCytidineBenzoatesNitrobenzenesPyrazolones

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of Respiratory and Critical Care Medicine, Jinling Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Pulmonary and Critical Care Medicine, Nanjing Second Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China; School of Integrated Chinese and Western Medicine, Nanjing…
  • Department of Cardiothoracic Surgery, Jinling Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address: luojing_2767983@163.com.

Förderung

  • Jiangsu Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Z., Wu, Q., Yao, Y., Cao, M., Ding, J., Xiao, Y., Huang, X., & Luo, J. (2026). Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis. International Immunopharmacology, 181, 116793. https://doi.org/10.1016/j.intimp.2026.116793

Vancouver

Wang Z, Wu Q, Yao Y, Cao M, Ding J, Xiao Y, et al. Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis. International Immunopharmacology. 2026;181:116793. doi:10.1016/j.intimp.2026.116793

BibTeX
@article{Wang2026,
  author = {Wang, Zimu and Wu, Qiuxia and Yao, Yu and Cao, Mengshu and Ding, Jingjing and Xiao, Yonglong and Huang, Xinmei and Luo, Jing},
  title = {Targeting the RNA acetyltransferase NAT10 attenuates pulmonary fibrosis via the ac4C-mediated regulation of the C/EBPβ-ITGA11 axis},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {181},
  pages = {116793},
  doi = {10.1016/j.intimp.2026.116793}
}
Kostenlos starten →